Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 2/2016

01-02-2016 | Scleroderma (J Varga, Section Editor)

Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Authors: Vincent Sobanski, David Launay, Eric Hachulla, Marc Humbert

Published in: Current Rheumatology Reports | Issue 2/2016

Login to get access

Abstract

Pulmonary arterial hypertension (PAH) is a severe condition causing significant morbidity and mortality in patients with systemic sclerosis (SSc). Despite the use of specific treatments, SSc-PAH survival remains poorer than in idiopathic PAH (IPAH). Recent therapeutic advances in PAH show a lower magnitude of response in SSc-PAH and a higher risk of adverse events, as compared to IPAH. The multifaceted underlying mechanisms and the multisystem nature of SSc probably explain part of the worse outcomes in SSc-PAH compared to IPAH. This review describes the current management of SSc-PAH with an emphasis on the impact of the different organ involvements in the prognosis and treatment response. An earlier detection of PAH and a better characterization of the clinical phenotypes of SSc-PAH are warranted in clinical practice and future trials. Determinants of prognosis, surrogate markers of clinical improvement or worsening, and relevance of the common endpoints used in clinical trials should be evaluated in this specific population. A multidisciplinary approach in expert referral centers is mandatory for SSc-PAH management.
Literature
1.
Komocsi A, Vorobcsuk A, Faludi R, Pinter T, Lenkey Z, Kolto G, et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology. 2012;51:1027–36.CrossRefPubMed
2.
Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–41.CrossRefPubMed
3.
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42–50.CrossRefPubMed
4.••
Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis–associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65:2412–23. This meta-analysis confirmed the poor prognosis of SSc-PAH. Baseline hemodynamics including right atrial pressure were associated with survival, but not the period of time during which patients were included in the studies.CrossRefPubMed
5.•
Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, et al. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis. 2012;71:249–52. This US multicenter study compared clinical characteristics between IPAH and SSc-PAH and confirmed a worse prognosis in SSc-PAH.CrossRefPubMed
6.
Launay D, Sitbon O, Le Pavec J, Savale L, Tcherakian C, Yaici A, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology. 2010;49:490–500.CrossRefPubMed
7.•
McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D73–81. Provides multiple treatment goals with specific values of the relevant parameters. Will need validation on the specific SSc-PAH population.CrossRefPubMed
8.
McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62:D51–9.CrossRefPubMed
9.••
Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75. 2015 ESC/ERS Guidelines for the diagnosis and treatment of PH.CrossRefPubMed
10.
Avouac J, Airò P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheum J Rheum. 2010;37:2290–8.CrossRefPubMed
11.••
Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Annals of the Rheumatic Diseases. BMJ Publishing Group Ltd and European League Against Rheumatism; 2014;73:1340–9. Provides a novel evidence-based algorithm for PAH detection in SSc. Two steps are proposed using non-echocardiographic and echocardiographic variables.
12.
Hachulla E, De Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis & Rheumatism. Wiley Subscription Services, Inc., A Wiley Company; 2009;60:1831–9
13.
Overbeek MJ, Vonk MC, Boonstra A, Voskuyl AE, Vonk-Noordegraaf A, Smit EF, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J Eur Respir Soc. 2009;34:371–9.CrossRef
14.
Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Müller K-M, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol. 2007;38:893–902.CrossRefPubMed
15.•
McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65:1976–97. The management of PAH is reviewed, especially the cardiac evaluation using echocardiography and RHC (differentiation between PAH and PH-LHD, evaluation of RV function).CrossRefPubMed
16.
Kherbeck N, Tamby MC, Bussone G, Dib H, Perros F, Humbert M, et al. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clinical Reviews in Allergy \& Immunology. Humana Press Inc; 2013;44:31–8
17.
Bussone G, Tamby MC, Calzas C, Kherbeck N, Sahbatou Y, Sanson C, et al. IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis. 2012;71:596–605.CrossRefPubMed
18.•
Becker MO, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C, et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med Am Thorac Soc. 2014;190:808–17. Vascular receptor autoantibodies may contribute to SSc-PAH via increased vascular endothelial reactivity and induction of pulmonary vasculopathy.CrossRef
19.
Muangchan C. Canadian Scleroderma Research Group, Baron M, Pope J. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. The Journal of rheumatology. J Rheum. 2013;40:1545–56.CrossRefPubMed
20.
Hachulla E, Launay D, Mouthon L, Sitbon O, Berezne A, Guillevin L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest. 2009;136:1211–9.CrossRefPubMed
21.
Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum. 2014;66:1625–35.CrossRef
22.
Le Pavec J, Girgis RE, Lechtzin N, Mathai SC, Launay D, Hummers LK, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum. 2011;63:2456–64.CrossRefPubMed
23.
Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JSR, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179:151–7.CrossRefPubMed
24.
Le Pavec J, Girgis RE, Lechtzin N, Mathai SC, Launay D, Hummers LK, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis & Rheumatism. Wiley Subscription Services, Inc., A Wiley Company; 2011;63:2456–64
25.•
Günther S, Jais X, Maitre S, Bérezné A, Dorfmüller P, Seferian A, et al. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis & Rheumatism. Wiley Subscription Services, Inc., A Wiley Company; 2012;64:2995–3005. HRCT signs of PVOD are frequently observed in SSc patients with pre-capillary PH and are associated with a high risk of pulmonary edema.
26.
Montani D, O'Callaghan DS, Savale L, Jaïs X, Yaici A, Maitre S, et al. Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med. 2010;104 Suppl 1:S23–32.CrossRefPubMed
27.
Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. Rheumatology (Oxford, England). Oxford University Press; 2009;48 Suppl 3:iii45–8.
28.
Hachulla A-L, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis. 2009;68:1878–84.CrossRefPubMedPubMedCentral
29.
Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis & Rheumatism. Wiley Subscription Services, Inc., A Wiley Company; 2006;54:3043–50.
30.••
Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J: Off J Eur Soc Clin Respir Physiol. 2013;42:1083–91. PH-LHD is frequent in SSc-PH population. The authors propose an additional testing with fluid challenge during left heart catheterization to diagnose PH-LHD in misclassified PAH patients.CrossRef
31.
Vachiery J-L, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol. 2013;62:D100–8.CrossRefPubMed
32.
Schoenfeld SR, Choi HK, Sayre EC, Aviña-Zubieta JA. The risk of pulmonary embolism and deep venous thrombosis in systemic sclerosis: A general population-based study. Arthritis Care \& Research. 2015;:n/a–n/a.
33.
Morrisroe KB, Stevens W, Nandurkar H, Prior D, Thakkar V, Roddy J, et al. The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis. Clin Exp Rheumatol. 2014;32:S–133–7.PubMed
34.
Meier FMP, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Annals of the Rheumatic Diseases. BMJ Publishing Group Ltd and European League Against Rheumatism; 2012;71:1355–60.
35.
Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J Eur Respir Soc. 2011;37:1386–91.CrossRef
36.
Ruiter G, Lanser IJ, de Man FS, van der Laarse WJ, Wharton J, Wilkins MR, et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology (Oxford, England). Oxford University Press; 2014;53:285–92.
37.
Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing Z-C, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62:D60–72.CrossRefPubMed
38.•
Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. Lippincott Williams & Wilkins; 2014;129:57–65. This analysis of a European PAH registry suggested a survival benefit with oral anticoagulation for IPAH. In SSc-PAH, there was a trend toward a worse survival in patients receiving anticoagulants.
39.
Ngian G-S, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Research \& Therapy. BioMed Central Ltd; 2012;14:R213.
40.
Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Le T, Lee P, et al. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheum J Rheum. 2012;39:276–85.CrossRefPubMed
41.
Preston IR, Roberts KE, Miller DP, Hill NS, Farber HW. Effect Of Warfarin Treatment On Survival of Patients With Pulmonary Arterial Hypertension (PAH) In The Registry To Evaluate Early And Long-Term PAH Disease Management (REVEAL). American Thoracic Society International Conference Abstracts. American Thoracic Society; 2014. pp. A2464–4.
42.•
Kuwana M, Watanabe H, Matsuoka N, Sugiyama N. Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials. BMJ Open. 2013;3:e003113–3. This meta-analysis suggested that ERAs bosentan and ambrisentan may be less effective in patients with CTD-PAH than in those with PAH generally. However there were limitations due to the limited number of studies dedicated to CTD-PAH and the small number of CTD-PAH patients included in others.CrossRef
43.
Montani D, Savale L, Natali D, Jaïs X, Herve P, Garcia G, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. European heart journal. The Oxford University Press; 2010;31:1898–907.
44.
Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet. 2001;358:1119–23.CrossRefPubMed
45.
Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903.CrossRefPubMed
46.
Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–100.CrossRefPubMed
47.
Denton CP. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006;65:1336–40.CrossRefPubMedPubMedCentral
48.
Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. BMJ Publishing Group Ltd and European League Against Rheumatism; 2011;70:32–8.
49.
Badesch DB. Ambrisentan therapy for pulmonary arterial hypertension: a comparison by PAH etiology. Chest Am Coll Chest Phys. 2007;132:488b–9b.
50.
Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovascular Therapeutics. Blackwell Publishing Ltd; 2012;30:93–9.
51.
Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Int Med Am Coll Phys. 2013;158:641–9.CrossRef
52.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–18.CrossRefPubMed
53.
Channick RN, Delcroix M, Ghofrani H-A, Hunsche E, Jansa P, Le Brun F-O, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015;3:1–8.CrossRefPubMed
54.
Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–57.CrossRefPubMed
55.
Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation. 2009;119:2894–903.CrossRefPubMed
56.
Jing Z-C, Yu Z-X, Shen J-Y, Wu B-X, Xu K-F, Zhu X-Y, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med Am Thorac Soc. 2011;183:1723–9.CrossRef
57.
Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheum. 2007;34:2417–22.PubMed
58.
Ghofrani H-A, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330–40.CrossRefPubMed
59.
Galiè N, Müller K, Scalise A-V, Grünig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45:1314–22.CrossRefPubMed
60.
Simonneau G, Barst RJ, Galiè N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–4.CrossRefPubMed
61.
Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322–9.CrossRefPubMed
62.
Galiè N, Humbert M, Vachiery J-L, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496–502.CrossRefPubMed
63.
Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119–25.CrossRefPubMed
64.
Tapson VF. Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study). Chest. 2012;142:1383–8.CrossRefPubMed
65.
Tapson VF. Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study). Chest. 2013;144:952–7.CrossRefPubMed
66.
Jing Z-C, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. Lippincott Williams & Wilkins; 2013;127:624–33
67.
Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425–34.CrossRefPubMed
68.
Oudiz RJ, Schilz RJ, Barst RJ, Galiè N, Rich S, Rubin LJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest Am Coll Chest Physicians. 2004;126:420–7.
69.
Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlócai K, Galiè N, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J Eur Respir Soc. 2012;40:874–80.CrossRef
70.
McLaughlin VV, Channick R, Chin K, Frey A, Gaine S, Ghofrani A, et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the Griphon Study. J Am Coll Cardiol Am Coll Cardiol Found. 2015;65:A1538.CrossRef
71.
Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J Off J Eur Soc Clin Respir Physiol. 2004;24:353–9.
72.
McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257–63.CrossRefPubMed
73.
Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521–30.CrossRefPubMed
74.
McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. Elsevier Inc; 2010;55:1915–22.
75.
McLaughlin V, Channick RN, Ghofrani H-A, Lemarié J-C, Naeije R, Packer M, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46:405–13.CrossRefPubMed
76.
Galiè N, Barberà JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834–44.CrossRefPubMed
77.
Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, et al. Ambrisentan and Tadalafil Upfront Combination Therapy in Scleroderma-Associated PAH. Am J Respir Crit Care Med. 2015;:rccm.201507–1398OC–43.
78.•
Johnson SR, Brode SK, Mielniczuk LM, Granton JT. Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. Respiratory Medicine. Elsevier Ltd; 2012;106:730–9. A systematic review suggesting a beneficial effect of dual therapy in IPAH and SSc-PAH
79.
Saggar R, Khanna D, Furst DE, Belperio JA, Park GS, Weigt SS, et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J Eur Respir Soc. 2010;36:893–900.CrossRef
80.
Schachna L, Medsger TA, Dauber JH, Wigley FM, Braunstein NA, White B, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis & Rheumatism. Wiley Subscription Services, Inc., A Wiley Company; 2006;54:3954–61.
81.
Launay D, Savale L, Berezne A, Le Pavec J, Hachulla E, Mouthon L, et al. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Médicale (Paris, France: 1983). 2014;43:e345–63.
82.
Bournia V-K, Evangelou K, Sfikakis PP. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib. Semin Arthritis Rheum. 2013;42:377–90.CrossRefPubMed
83.
Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galiè N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. Lippincott Williams & Wilkins; 2013;127:1128–38.
84.
Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest Am Coll Chest Physicians. 2006;130:182–9.
85.
Jaïs X, Launay D, Yaici A, Le Pavec J, Tchérakian C, Sitbon O, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis & Rheumatism. Wiley Subscription Services, Inc., A Wiley Company; 2008;58:521–31.
86.
Sobanski V, Giovannelli J, Lynch BM, Schreiber BE, Nihtyanova SI, Harvey J, et al. Characteristics and survival of patients with anti-U1RNP antibodies in connective tissue disease associated pulmonary arterial hypertension. Arthritis & Rheumatology. 2015;:n/a–n/a.
87.
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) - Full Text View - ClinicalTrials.gov.
88.••
Sanges S, Launay D, Rhee RL, Sitbon O, Hachulla E, Mouthon L, et al. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. Annals of the Rheumatic Diseases. 2015;:annrheumdis–2015–207336. The authors showed within two cohorts that non-hemodynamic factors could have an impact on the 6MWD in SSc-PAH. There was no association between the changes in 6MWD and hemodynamic parameters during follow-up suggesting that 6MWD may not be an appropriate surrogate marker of hemodynamic outcomes in treated SSc-PAH.
89.
Savarese G, Paolillo S, Costanzo P, D'Amore C, Cecere M, Losco T, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60:1192–201.CrossRefPubMed
90.
Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest Am Coll Chest Physicians. 2010;138:1383–94.
91.
Denton CP, Avouac J, Behrens F, Furst DE, Foeldvári I, Humbert M, et al. Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Research \& Therapy. BioMed Central Ltd; 2011;13:114.
92.
Simonneau G, Galiè N, Jansa P, Meyer GMB, Hiti Al H, Kusic-Pajic A, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014;172:332–9.CrossRefPubMed
93.•
Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis & Rheumatism. 2013. pp. 3194–201. Consensus-based, evidence-driven recommendations for screening and early detection of CTD-PAH
94.
Humbert M, Yaici A, De Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 2011;63:3522–30.CrossRefPubMed
95.
Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirják L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620–8.CrossRefPubMed
96.
Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation. 2008;117:3010–9.CrossRefPubMed
97.
Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005;171:1292–7.CrossRefPubMed
Metadata
Title
Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Authors
Vincent Sobanski
David Launay
Eric Hachulla
Marc Humbert
Publication date
01-02-2016
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 2/2016
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0560-x

Other articles of this Issue 2/2016

Current Rheumatology Reports 2/2016 Go to the issue

Antiphospholipid Syndrome (S Zuily, Section Editor)

Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome

Pediatric Rheumatology (S Ozen, Section Editor)

Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases

Antiphospholipid Syndrome (S Zuily, Section Editor)

Organ Damage and Quality of Life in Antiphospholipid Syndrome

Spondyloarthritis (MA Khan, Section Editor)

Causality of Chlamydiae in Arthritis and Spondyloarthritis: a Plea for Increased Translational Research

Scleroderma (J Varga, Section Editor)

Cellular Therapies in Systemic Sclerosis: Recent Progress
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits